nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—CA9—kidney cancer	0.618	1	CbGaD
Metolazone—SLC12A3—collecting duct of renal tubule—kidney cancer	0.0342	0.425	CbGeAlD
Metolazone—SLC12A3—nephron—kidney cancer	0.0152	0.189	CbGeAlD
Metolazone—CA9—Reversible hydration of carbon dioxide—CA2—kidney cancer	0.00386	0.037	CbGpPWpGaD
Metolazone—CA4—Reversible hydration of carbon dioxide—CA9—kidney cancer	0.00362	0.0347	CbGpPWpGaD
Metolazone—SLC12A3—nephron tubule—kidney cancer	0.00329	0.0408	CbGeAlD
Metolazone—CA7—renal system—kidney cancer	0.00305	0.0379	CbGeAlD
Metolazone—SLC12A3—renal system—kidney cancer	0.00299	0.0371	CbGeAlD
Metolazone—CA7—kidney—kidney cancer	0.00295	0.0366	CbGeAlD
Metolazone—SLC12A3—kidney—kidney cancer	0.00289	0.0359	CbGeAlD
Metolazone—SLC12A3—cortex of kidney—kidney cancer	0.00281	0.0349	CbGeAlD
Metolazone—CA9—Cellular response to hypoxia—VHL—kidney cancer	0.002	0.0191	CbGpPWpGaD
Metolazone—CA9—Cellular response to hypoxia—EPAS1—kidney cancer	0.002	0.0191	CbGpPWpGaD
Metolazone—CA12—renal system—kidney cancer	0.00198	0.0246	CbGeAlD
Metolazone—CA12—kidney—kidney cancer	0.00192	0.0238	CbGeAlD
Metolazone—CA9—Cellular response to hypoxia—TCEB1—kidney cancer	0.00175	0.0168	CbGpPWpGaD
Metolazone—CA9—Cellular response to hypoxia—TCEB2—kidney cancer	0.00175	0.0168	CbGpPWpGaD
Metolazone—CA5B—gonad—kidney cancer	0.00159	0.0198	CbGeAlD
Metolazone—CA5B—cardiac atrium—kidney cancer	0.00159	0.0198	CbGeAlD
Metolazone—CA9—Regulation of gene expression by Hypoxia-inducible Factor—HIF1A—kidney cancer	0.00143	0.0137	CbGpPWpGaD
Metolazone—CA4—nephron tubule—kidney cancer	0.00135	0.0168	CbGeAlD
Metolazone—CA4—renal system—kidney cancer	0.00123	0.0152	CbGeAlD
Metolazone—CA4—kidney—kidney cancer	0.00119	0.0147	CbGeAlD
Metolazone—CA4—cortex of kidney—kidney cancer	0.00116	0.0143	CbGeAlD
Metolazone—CA4—cardiac atrium—kidney cancer	0.0011	0.0136	CbGeAlD
Metolazone—CA9—HIF-1-alpha transcription factor network—PGK1—kidney cancer	0.00088	0.00843	CbGpPWpGaD
Metolazone—Benzthiazide—CA9—kidney cancer	0.000871	0.122	CrCbGaD
Metolazone—Indapamide—CA9—kidney cancer	0.000865	0.121	CrCbGaD
Metolazone—Quinethazone—CA2—kidney cancer	0.000843	0.118	CrCbGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—NDRG1—kidney cancer	0.000818	0.00784	CbGpPWpGaD
Metolazone—Methyclothiazide—CA2—kidney cancer	0.000808	0.113	CrCbGaD
Metolazone—Benzthiazide—CA2—kidney cancer	0.000784	0.11	CrCbGaD
Metolazone—Chlorothiazide—CA2—kidney cancer	0.000778	0.109	CrCbGaD
Metolazone—Indapamide—CA2—kidney cancer	0.000778	0.109	CrCbGaD
Metolazone—CA9—Regulation of gene expression by Hypoxia-inducible Factor—VEGFA—kidney cancer	0.000751	0.00719	CbGpPWpGaD
Metolazone—Chlorthalidone—CA9—kidney cancer	0.000745	0.104	CrCbGaD
Metolazone—Chlorthalidone—CA2—kidney cancer	0.00067	0.0937	CrCbGaD
Metolazone—CA9—Cellular response to hypoxia—HIF1A—kidney cancer	0.00063	0.00603	CbGpPWpGaD
Metolazone—SLC12A3—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—kidney cancer	0.000498	0.00476	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—SLC2A1—kidney cancer	0.000448	0.00429	CbGpPWpGaD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000422	0.00404	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000373	0.00357	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—ABCB1—kidney cancer	0.000354	0.00339	CbGpPWpGaD
Metolazone—CA9—Cellular response to hypoxia—VEGFA—kidney cancer	0.000332	0.00318	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—IGFBP7—kidney cancer	0.000318	0.00304	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—VHL—kidney cancer	0.000303	0.0029	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—EPAS1—kidney cancer	0.000303	0.0029	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—HIF1A—kidney cancer	0.00029	0.00277	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—TCEB2—kidney cancer	0.000266	0.00254	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—TCEB1—kidney cancer	0.000266	0.00254	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ACY1—kidney cancer	0.000239	0.00229	CbGpPWpGaD
Metolazone—CA7—Metabolism—ACY1—kidney cancer	0.000223	0.00214	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ACY1—kidney cancer	0.000223	0.00214	CbGpPWpGaD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000222	0.00213	CbGpPWpGaD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000215	0.00206	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000214	0.00205	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000214	0.00205	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000214	0.00205	CbGpPWpGaD
Metolazone—CA12—Metabolism—ACY1—kidney cancer	0.000207	0.00198	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PDHB—kidney cancer	0.000203	0.00195	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CCBL1—kidney cancer	0.000191	0.00183	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PDHB—kidney cancer	0.00019	0.00182	CbGpPWpGaD
Metolazone—CA7—Metabolism—PDHB—kidney cancer	0.00019	0.00182	CbGpPWpGaD
Metolazone—Anorexia—Vincristine—kidney cancer	0.000183	0.000967	CcSEcCtD
Metolazone—Dysgeusia—Paclitaxel—kidney cancer	0.000183	0.000966	CcSEcCtD
Metolazone—Nervousness—Paclitaxel—kidney cancer	0.000182	0.000958	CcSEcCtD
Metolazone—Back pain—Paclitaxel—kidney cancer	0.000181	0.000954	CcSEcCtD
Metolazone—Dizziness—Vinblastine—kidney cancer	0.000181	0.000953	CcSEcCtD
Metolazone—Dizziness—Everolimus—kidney cancer	0.00018	0.000949	CcSEcCtD
Metolazone—Muscle spasms—Paclitaxel—kidney cancer	0.00018	0.000949	CcSEcCtD
Metolazone—Abdominal pain—Sunitinib—kidney cancer	0.00018	0.000948	CcSEcCtD
Metolazone—Diarrhoea—Erlotinib—kidney cancer	0.00018	0.000947	CcSEcCtD
Metolazone—Thrombocytopenia—Gemcitabine—kidney cancer	0.000179	0.000942	CcSEcCtD
Metolazone—CA7—Metabolism—CCBL1—kidney cancer	0.000178	0.00171	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CCBL1—kidney cancer	0.000178	0.00171	CbGpPWpGaD
Metolazone—Feeling abnormal—Dactinomycin—kidney cancer	0.000177	0.000935	CcSEcCtD
Metolazone—Hepatitis—Capecitabine—kidney cancer	0.000176	0.00093	CcSEcCtD
Metolazone—Vision blurred—Paclitaxel—kidney cancer	0.000176	0.00093	CcSEcCtD
Metolazone—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000176	0.000928	CcSEcCtD
Metolazone—CA12—Metabolism—PDHB—kidney cancer	0.000176	0.00168	CbGpPWpGaD
Metolazone—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000175	0.000924	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—JUN—kidney cancer	0.000175	0.00167	CbGpPWpGaD
Metolazone—Hypersensitivity—Sorafenib—kidney cancer	0.000174	0.000918	CcSEcCtD
Metolazone—Insomnia—Vincristine—kidney cancer	0.000174	0.000917	CcSEcCtD
Metolazone—Anorexia—Gemcitabine—kidney cancer	0.000174	0.000917	CcSEcCtD
Metolazone—Vomiting—Vinblastine—kidney cancer	0.000174	0.000916	CcSEcCtD
Metolazone—Dizziness—Erlotinib—kidney cancer	0.000174	0.000916	CcSEcCtD
Metolazone—Ill-defined disorder—Paclitaxel—kidney cancer	0.000174	0.000916	CcSEcCtD
Metolazone—Vomiting—Everolimus—kidney cancer	0.000173	0.000913	CcSEcCtD
Metolazone—Anaemia—Paclitaxel—kidney cancer	0.000173	0.000912	CcSEcCtD
Metolazone—Paraesthesia—Vincristine—kidney cancer	0.000173	0.00091	CcSEcCtD
Metolazone—Agitation—Paclitaxel—kidney cancer	0.000172	0.000907	CcSEcCtD
Metolazone—Rash—Everolimus—kidney cancer	0.000172	0.000905	CcSEcCtD
Metolazone—Dermatitis—Everolimus—kidney cancer	0.000172	0.000904	CcSEcCtD
Metolazone—Headache—Vinblastine—kidney cancer	0.000171	0.000903	CcSEcCtD
Metolazone—Purpura—Doxorubicin—kidney cancer	0.000171	0.000899	CcSEcCtD
Metolazone—Headache—Everolimus—kidney cancer	0.000171	0.000899	CcSEcCtD
Metolazone—Abdominal pain—Dactinomycin—kidney cancer	0.00017	0.000897	CcSEcCtD
Metolazone—Asthenia—Sorafenib—kidney cancer	0.00017	0.000894	CcSEcCtD
Metolazone—Malaise—Paclitaxel—kidney cancer	0.000169	0.00089	CcSEcCtD
Metolazone—Vertigo—Paclitaxel—kidney cancer	0.000168	0.000887	CcSEcCtD
Metolazone—Syncope—Paclitaxel—kidney cancer	0.000168	0.000885	CcSEcCtD
Metolazone—Lethargy—Doxorubicin—kidney cancer	0.000168	0.000885	CcSEcCtD
Metolazone—Leukopenia—Paclitaxel—kidney cancer	0.000168	0.000883	CcSEcCtD
Metolazone—Hypersensitivity—Sunitinib—kidney cancer	0.000168	0.000883	CcSEcCtD
Metolazone—Decreased appetite—Vincristine—kidney cancer	0.000167	0.000881	CcSEcCtD
Metolazone—Pruritus—Sorafenib—kidney cancer	0.000167	0.000881	CcSEcCtD
Metolazone—Vomiting—Erlotinib—kidney cancer	0.000167	0.00088	CcSEcCtD
Metolazone—Erythema multiforme—Capecitabine—kidney cancer	0.000167	0.00088	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000166	0.000876	CcSEcCtD
Metolazone—Fatigue—Vincristine—kidney cancer	0.000166	0.000874	CcSEcCtD
Metolazone—CA5A—Metabolism—GLIPR1—kidney cancer	0.000166	0.00159	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PPAT—kidney cancer	0.000166	0.00159	CbGpPWpGaD
Metolazone—Rash—Erlotinib—kidney cancer	0.000166	0.000873	CcSEcCtD
Metolazone—Dermatitis—Erlotinib—kidney cancer	0.000165	0.000872	CcSEcCtD
Metolazone—Palpitations—Paclitaxel—kidney cancer	0.000165	0.000872	CcSEcCtD
Metolazone—CA12—Metabolism—CCBL1—kidney cancer	0.000165	0.00158	CbGpPWpGaD
Metolazone—Hyponatraemia—Doxorubicin—kidney cancer	0.000165	0.00087	CcSEcCtD
Metolazone—Insomnia—Gemcitabine—kidney cancer	0.000165	0.00087	CcSEcCtD
Metolazone—CA4—Metabolism—ACY1—kidney cancer	0.000165	0.00158	CbGpPWpGaD
Metolazone—Headache—Erlotinib—kidney cancer	0.000165	0.000868	CcSEcCtD
Metolazone—Tinnitus—Capecitabine—kidney cancer	0.000165	0.000867	CcSEcCtD
Metolazone—Loss of consciousness—Paclitaxel—kidney cancer	0.000165	0.000867	CcSEcCtD
Metolazone—Constipation—Vincristine—kidney cancer	0.000164	0.000867	CcSEcCtD
Metolazone—Pain—Vincristine—kidney cancer	0.000164	0.000867	CcSEcCtD
Metolazone—Paraesthesia—Gemcitabine—kidney cancer	0.000164	0.000864	CcSEcCtD
Metolazone—Cough—Paclitaxel—kidney cancer	0.000163	0.000861	CcSEcCtD
Metolazone—Asthenia—Sunitinib—kidney cancer	0.000163	0.00086	CcSEcCtD
Metolazone—Nausea—Vinblastine—kidney cancer	0.000162	0.000856	CcSEcCtD
Metolazone—Somnolence—Gemcitabine—kidney cancer	0.000162	0.000855	CcSEcCtD
Metolazone—Nausea—Everolimus—kidney cancer	0.000162	0.000852	CcSEcCtD
Metolazone—Diarrhoea—Sorafenib—kidney cancer	0.000162	0.000852	CcSEcCtD
Metolazone—Hypertension—Paclitaxel—kidney cancer	0.000162	0.000852	CcSEcCtD
Metolazone—Pruritus—Sunitinib—kidney cancer	0.000161	0.000848	CcSEcCtD
Metolazone—Chest pain—Paclitaxel—kidney cancer	0.000159	0.00084	CcSEcCtD
Metolazone—Arthralgia—Paclitaxel—kidney cancer	0.000159	0.00084	CcSEcCtD
Metolazone—Anxiety—Paclitaxel—kidney cancer	0.000159	0.000837	CcSEcCtD
Metolazone—Decreased appetite—Gemcitabine—kidney cancer	0.000159	0.000836	CcSEcCtD
Metolazone—Hypersensitivity—Dactinomycin—kidney cancer	0.000159	0.000836	CcSEcCtD
Metolazone—Chills—Capecitabine—kidney cancer	0.000158	0.000835	CcSEcCtD
Metolazone—Discomfort—Paclitaxel—kidney cancer	0.000157	0.00083	CcSEcCtD
Metolazone—Fatigue—Gemcitabine—kidney cancer	0.000157	0.000829	CcSEcCtD
Metolazone—Gastrointestinal pain—Vincristine—kidney cancer	0.000157	0.000829	CcSEcCtD
Metolazone—Dizziness—Sorafenib—kidney cancer	0.000156	0.000824	CcSEcCtD
Metolazone—Constipation—Gemcitabine—kidney cancer	0.000156	0.000823	CcSEcCtD
Metolazone—Pain—Gemcitabine—kidney cancer	0.000156	0.000823	CcSEcCtD
Metolazone—Nausea—Erlotinib—kidney cancer	0.000156	0.000823	CcSEcCtD
Metolazone—Dry mouth—Paclitaxel—kidney cancer	0.000156	0.000822	CcSEcCtD
Metolazone—Diarrhoea—Sunitinib—kidney cancer	0.000156	0.00082	CcSEcCtD
Metolazone—CA7—Metabolism—PPAT—kidney cancer	0.000155	0.00148	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PPAT—kidney cancer	0.000155	0.00148	CbGpPWpGaD
Metolazone—CA7—Metabolism—GLIPR1—kidney cancer	0.000155	0.00148	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GLIPR1—kidney cancer	0.000155	0.00148	CbGpPWpGaD
Metolazone—Asthenia—Dactinomycin—kidney cancer	0.000154	0.000814	CcSEcCtD
Metolazone—CA5A—Metabolism—FH—kidney cancer	0.000154	0.00147	CbGpPWpGaD
Metolazone—CA5A—Metabolism—APRT—kidney cancer	0.000154	0.00147	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	0.000153	0.00146	CbGpPWpGaD
Metolazone—Abdominal pain—Vincristine—kidney cancer	0.000152	0.000802	CcSEcCtD
Metolazone—Flatulence—Capecitabine—kidney cancer	0.000151	0.000798	CcSEcCtD
Metolazone—Dry skin—Doxorubicin—kidney cancer	0.000151	0.000794	CcSEcCtD
Metolazone—Dysgeusia—Capecitabine—kidney cancer	0.00015	0.000793	CcSEcCtD
Metolazone—Dizziness—Sunitinib—kidney cancer	0.00015	0.000793	CcSEcCtD
Metolazone—Feeling abnormal—Gemcitabine—kidney cancer	0.00015	0.000793	CcSEcCtD
Metolazone—Shock—Paclitaxel—kidney cancer	0.00015	0.000792	CcSEcCtD
Metolazone—Vomiting—Sorafenib—kidney cancer	0.00015	0.000792	CcSEcCtD
Metolazone—Orthostatic hypotension—Doxorubicin—kidney cancer	0.00015	0.000792	CcSEcCtD
Metolazone—Hypokalaemia—Doxorubicin—kidney cancer	0.00015	0.000789	CcSEcCtD
Metolazone—Thrombocytopenia—Paclitaxel—kidney cancer	0.00015	0.000789	CcSEcCtD
Metolazone—Rash—Sorafenib—kidney cancer	0.000149	0.000786	CcSEcCtD
Metolazone—Dermatitis—Sorafenib—kidney cancer	0.000149	0.000785	CcSEcCtD
Metolazone—Back pain—Capecitabine—kidney cancer	0.000149	0.000783	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000148	0.000781	CcSEcCtD
Metolazone—Headache—Sorafenib—kidney cancer	0.000148	0.00078	CcSEcCtD
Metolazone—Muscle spasms—Capecitabine—kidney cancer	0.000148	0.000779	CcSEcCtD
Metolazone—Diarrhoea—Dactinomycin—kidney cancer	0.000147	0.000776	CcSEcCtD
Metolazone—Anorexia—Paclitaxel—kidney cancer	0.000146	0.000768	CcSEcCtD
Metolazone—CA5A—Metabolism—GPC3—kidney cancer	0.000145	0.00139	CbGpPWpGaD
Metolazone—Vision blurred—Capecitabine—kidney cancer	0.000145	0.000763	CcSEcCtD
Metolazone—Vomiting—Sunitinib—kidney cancer	0.000145	0.000762	CcSEcCtD
Metolazone—CA5B—Metabolism—FH—kidney cancer	0.000144	0.00138	CbGpPWpGaD
Metolazone—CA7—Metabolism—FH—kidney cancer	0.000144	0.00138	CbGpPWpGaD
Metolazone—CA7—Metabolism—APRT—kidney cancer	0.000144	0.00138	CbGpPWpGaD
Metolazone—CA5B—Metabolism—APRT—kidney cancer	0.000144	0.00138	CbGpPWpGaD
Metolazone—Rash—Sunitinib—kidney cancer	0.000143	0.000756	CcSEcCtD
Metolazone—CA12—Metabolism—GLIPR1—kidney cancer	0.000143	0.00137	CbGpPWpGaD
Metolazone—CA12—Metabolism—PPAT—kidney cancer	0.000143	0.00137	CbGpPWpGaD
Metolazone—Dermatitis—Sunitinib—kidney cancer	0.000143	0.000755	CcSEcCtD
Metolazone—Abdominal distension—Doxorubicin—kidney cancer	0.000143	0.000754	CcSEcCtD
Metolazone—Ill-defined disorder—Capecitabine—kidney cancer	0.000143	0.000751	CcSEcCtD
Metolazone—Headache—Sunitinib—kidney cancer	0.000142	0.000751	CcSEcCtD
Metolazone—Anaemia—Capecitabine—kidney cancer	0.000142	0.000748	CcSEcCtD
Metolazone—Hypersensitivity—Vincristine—kidney cancer	0.000142	0.000747	CcSEcCtD
Metolazone—CA5A—Metabolism—CA2—kidney cancer	0.000141	0.00135	CbGpPWpGaD
Metolazone—Nausea—Sorafenib—kidney cancer	0.00014	0.00074	CcSEcCtD
Metolazone—CA4—Metabolism—PDHB—kidney cancer	0.00014	0.00134	CbGpPWpGaD
Metolazone—Pancreatitis—Doxorubicin—kidney cancer	0.000139	0.000734	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000139	0.000734	CcSEcCtD
Metolazone—Malaise—Capecitabine—kidney cancer	0.000139	0.00073	CcSEcCtD
Metolazone—Insomnia—Paclitaxel—kidney cancer	0.000138	0.000728	CcSEcCtD
Metolazone—Vertigo—Capecitabine—kidney cancer	0.000138	0.000728	CcSEcCtD
Metolazone—Asthenia—Vincristine—kidney cancer	0.000138	0.000727	CcSEcCtD
Metolazone—Syncope—Capecitabine—kidney cancer	0.000138	0.000726	CcSEcCtD
Metolazone—Leukopenia—Capecitabine—kidney cancer	0.000138	0.000725	CcSEcCtD
Metolazone—CA5A—Metabolism—ALAD—kidney cancer	0.000137	0.00131	CbGpPWpGaD
Metolazone—Paraesthesia—Paclitaxel—kidney cancer	0.000137	0.000723	CcSEcCtD
Metolazone—Vomiting—Dactinomycin—kidney cancer	0.000137	0.000722	CcSEcCtD
Metolazone—Somnolence—Paclitaxel—kidney cancer	0.000136	0.000716	CcSEcCtD
Metolazone—Palpitations—Capecitabine—kidney cancer	0.000136	0.000716	CcSEcCtD
Metolazone—Rash—Dactinomycin—kidney cancer	0.000136	0.000716	CcSEcCtD
Metolazone—CA5B—Metabolism—GPC3—kidney cancer	0.000135	0.00129	CbGpPWpGaD
Metolazone—CA7—Metabolism—GPC3—kidney cancer	0.000135	0.00129	CbGpPWpGaD
Metolazone—Nausea—Sunitinib—kidney cancer	0.000135	0.000712	CcSEcCtD
Metolazone—Loss of consciousness—Capecitabine—kidney cancer	0.000135	0.000712	CcSEcCtD
Metolazone—Dyspepsia—Paclitaxel—kidney cancer	0.000134	0.000709	CcSEcCtD
Metolazone—Cough—Capecitabine—kidney cancer	0.000134	0.000707	CcSEcCtD
Metolazone—CA5A—Metabolism—ST3GAL2—kidney cancer	0.000134	0.00128	CbGpPWpGaD
Metolazone—CA12—Metabolism—APRT—kidney cancer	0.000133	0.00128	CbGpPWpGaD
Metolazone—CA12—Metabolism—FH—kidney cancer	0.000133	0.00128	CbGpPWpGaD
Metolazone—CA9—Metabolism—ACY1—kidney cancer	0.000133	0.00128	CbGpPWpGaD
Metolazone—Decreased appetite—Paclitaxel—kidney cancer	0.000133	0.0007	CcSEcCtD
Metolazone—Hypertension—Capecitabine—kidney cancer	0.000133	0.000699	CcSEcCtD
Metolazone—CA4—Metabolism—CCBL1—kidney cancer	0.000132	0.00126	CbGpPWpGaD
Metolazone—Fatigue—Paclitaxel—kidney cancer	0.000132	0.000694	CcSEcCtD
Metolazone—Diarrhoea—Vincristine—kidney cancer	0.000132	0.000694	CcSEcCtD
Metolazone—CA5B—Metabolism—CA2—kidney cancer	0.000131	0.00126	CbGpPWpGaD
Metolazone—CA7—Metabolism—CA2—kidney cancer	0.000131	0.00126	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ALDH1A1—kidney cancer	0.000131	0.00125	CbGpPWpGaD
Metolazone—Asthenia—Gemcitabine—kidney cancer	0.000131	0.00069	CcSEcCtD
Metolazone—Arthralgia—Capecitabine—kidney cancer	0.000131	0.000689	CcSEcCtD
Metolazone—Chest pain—Capecitabine—kidney cancer	0.000131	0.000689	CcSEcCtD
Metolazone—Pain—Paclitaxel—kidney cancer	0.000131	0.000689	CcSEcCtD
Metolazone—Constipation—Paclitaxel—kidney cancer	0.000131	0.000689	CcSEcCtD
Metolazone—Anxiety—Capecitabine—kidney cancer	0.00013	0.000687	CcSEcCtD
Metolazone—Photosensitivity reaction—Doxorubicin—kidney cancer	0.00013	0.000684	CcSEcCtD
Metolazone—Discomfort—Capecitabine—kidney cancer	0.000129	0.000681	CcSEcCtD
Metolazone—Pruritus—Gemcitabine—kidney cancer	0.000129	0.000681	CcSEcCtD
Metolazone—Hyperglycaemia—Doxorubicin—kidney cancer	0.000128	0.000676	CcSEcCtD
Metolazone—CA7—Metabolism—ALAD—kidney cancer	0.000128	0.00123	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ALAD—kidney cancer	0.000128	0.00123	CbGpPWpGaD
Metolazone—Dry mouth—Capecitabine—kidney cancer	0.000128	0.000674	CcSEcCtD
Metolazone—Nausea—Dactinomycin—kidney cancer	0.000128	0.000674	CcSEcCtD
Metolazone—Dizziness—Vincristine—kidney cancer	0.000127	0.00067	CcSEcCtD
Metolazone—Drowsiness—Doxorubicin—kidney cancer	0.000127	0.000668	CcSEcCtD
Metolazone—Feeling abnormal—Paclitaxel—kidney cancer	0.000126	0.000664	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000126	0.000662	CcSEcCtD
Metolazone—CA5A—Metabolism—SLC5A3—kidney cancer	0.000126	0.0012	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PGK1—kidney cancer	0.000126	0.0012	CbGpPWpGaD
Metolazone—CA12—Metabolism—GPC3—kidney cancer	0.000125	0.0012	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ST3GAL2—kidney cancer	0.000125	0.0012	CbGpPWpGaD
Metolazone—CA7—Metabolism—ST3GAL2—kidney cancer	0.000125	0.0012	CbGpPWpGaD
Metolazone—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000125	0.000659	CcSEcCtD
Metolazone—Diarrhoea—Gemcitabine—kidney cancer	0.000125	0.000658	CcSEcCtD
Metolazone—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000124	0.000655	CcSEcCtD
Metolazone—CA9—Cellular responses to stress—GSTP1—kidney cancer	0.000123	0.00118	CbGpPWpGaD
Metolazone—Shock—Capecitabine—kidney cancer	0.000123	0.00065	CcSEcCtD
Metolazone—CA5A—Metabolism—LDHB—kidney cancer	0.000123	0.00118	CbGpPWpGaD
Metolazone—Thrombocytopenia—Capecitabine—kidney cancer	0.000123	0.000647	CcSEcCtD
Metolazone—Vomiting—Vincristine—kidney cancer	0.000122	0.000645	CcSEcCtD
Metolazone—CA7—Metabolism—ALDH1A1—kidney cancer	0.000122	0.00117	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ALDH1A1—kidney cancer	0.000122	0.00117	CbGpPWpGaD
Metolazone—CA12—Metabolism—CA2—kidney cancer	0.000122	0.00117	CbGpPWpGaD
Metolazone—Urticaria—Paclitaxel—kidney cancer	0.000121	0.00064	CcSEcCtD
Metolazone—Rash—Vincristine—kidney cancer	0.000121	0.000639	CcSEcCtD
Metolazone—Dermatitis—Vincristine—kidney cancer	0.000121	0.000639	CcSEcCtD
Metolazone—Abdominal pain—Paclitaxel—kidney cancer	0.000121	0.000637	CcSEcCtD
Metolazone—Headache—Vincristine—kidney cancer	0.00012	0.000635	CcSEcCtD
Metolazone—CA9—Cellular responses to stress—CDKN2B—kidney cancer	0.00012	0.00114	CbGpPWpGaD
Metolazone—Epistaxis—Doxorubicin—kidney cancer	0.00012	0.00063	CcSEcCtD
Metolazone—Anorexia—Capecitabine—kidney cancer	0.00012	0.00063	CcSEcCtD
Metolazone—CA12—Metabolism—ALAD—kidney cancer	0.000119	0.00114	CbGpPWpGaD
Metolazone—Agranulocytosis—Doxorubicin—kidney cancer	0.000118	0.000623	CcSEcCtD
Metolazone—CA7—Metabolism—PGK1—kidney cancer	0.000117	0.00112	CbGpPWpGaD
Metolazone—CA7—Metabolism—SLC5A3—kidney cancer	0.000117	0.00112	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PGK1—kidney cancer	0.000117	0.00112	CbGpPWpGaD
Metolazone—CA5B—Metabolism—SLC5A3—kidney cancer	0.000117	0.00112	CbGpPWpGaD
Metolazone—Vomiting—Gemcitabine—kidney cancer	0.000116	0.000612	CcSEcCtD
Metolazone—CA12—Metabolism—ST3GAL2—kidney cancer	0.000116	0.00111	CbGpPWpGaD
Metolazone—Rash—Gemcitabine—kidney cancer	0.000115	0.000606	CcSEcCtD
Metolazone—Dermatitis—Gemcitabine—kidney cancer	0.000115	0.000606	CcSEcCtD
Metolazone—CA7—Metabolism—LDHB—kidney cancer	0.000115	0.0011	CbGpPWpGaD
Metolazone—CA5B—Metabolism—LDHB—kidney cancer	0.000115	0.0011	CbGpPWpGaD
Metolazone—Headache—Gemcitabine—kidney cancer	0.000114	0.000603	CcSEcCtD
Metolazone—CA4—Metabolism—PPAT—kidney cancer	0.000114	0.00109	CbGpPWpGaD
Metolazone—CA4—Metabolism—GLIPR1—kidney cancer	0.000114	0.00109	CbGpPWpGaD
Metolazone—Nausea—Vincristine—kidney cancer	0.000114	0.000602	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000114	0.000602	CcSEcCtD
Metolazone—CA9—Cellular responses to stress—SOD2—kidney cancer	0.000114	0.00109	CbGpPWpGaD
Metolazone—Hepatitis—Doxorubicin—kidney cancer	0.000114	0.0006	CcSEcCtD
Metolazone—Insomnia—Capecitabine—kidney cancer	0.000113	0.000598	CcSEcCtD
Metolazone—CA12—Metabolism—ALDH1A1—kidney cancer	0.000113	0.00108	CbGpPWpGaD
Metolazone—CA9—Metabolism—PDHB—kidney cancer	0.000113	0.00108	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000113	0.00108	CbGpPWpGaD
Metolazone—Paraesthesia—Capecitabine—kidney cancer	0.000113	0.000593	CcSEcCtD
Metolazone—Hypersensitivity—Paclitaxel—kidney cancer	0.000113	0.000593	CcSEcCtD
Metolazone—Dyspepsia—Capecitabine—kidney cancer	0.00011	0.000582	CcSEcCtD
Metolazone—Asthenia—Paclitaxel—kidney cancer	0.00011	0.000578	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000109	0.00104	CbGpPWpGaD
Metolazone—Decreased appetite—Capecitabine—kidney cancer	0.000109	0.000575	CcSEcCtD
Metolazone—CA12—Metabolism—PGK1—kidney cancer	0.000109	0.00104	CbGpPWpGaD
Metolazone—CA12—Metabolism—SLC5A3—kidney cancer	0.000109	0.00104	CbGpPWpGaD
Metolazone—Nausea—Gemcitabine—kidney cancer	0.000108	0.000571	CcSEcCtD
Metolazone—Fatigue—Capecitabine—kidney cancer	0.000108	0.00057	CcSEcCtD
Metolazone—Pruritus—Paclitaxel—kidney cancer	0.000108	0.00057	CcSEcCtD
Metolazone—Erythema multiforme—Doxorubicin—kidney cancer	0.000108	0.000567	CcSEcCtD
Metolazone—Pain—Capecitabine—kidney cancer	0.000107	0.000565	CcSEcCtD
Metolazone—Constipation—Capecitabine—kidney cancer	0.000107	0.000565	CcSEcCtD
Metolazone—CA5A—Metabolism—CA9—kidney cancer	0.000107	0.00102	CbGpPWpGaD
Metolazone—CA12—Metabolism—LDHB—kidney cancer	0.000106	0.00102	CbGpPWpGaD
Metolazone—CA9—Metabolism—CCBL1—kidney cancer	0.000106	0.00102	CbGpPWpGaD
Metolazone—CA4—Metabolism—FH—kidney cancer	0.000106	0.00102	CbGpPWpGaD
Metolazone—CA4—Metabolism—APRT—kidney cancer	0.000106	0.00102	CbGpPWpGaD
Metolazone—Tinnitus—Doxorubicin—kidney cancer	0.000106	0.000559	CcSEcCtD
Metolazone—Diarrhoea—Paclitaxel—kidney cancer	0.000105	0.000551	CcSEcCtD
Metolazone—Feeling abnormal—Capecitabine—kidney cancer	0.000103	0.000545	CcSEcCtD
Metolazone—Gastrointestinal pain—Capecitabine—kidney cancer	0.000103	0.00054	CcSEcCtD
Metolazone—Chills—Doxorubicin—kidney cancer	0.000102	0.000538	CcSEcCtD
Metolazone—Dizziness—Paclitaxel—kidney cancer	0.000101	0.000533	CcSEcCtD
Metolazone—CA4—Metabolism—GPC3—kidney cancer	9.99e-05	0.000956	CbGpPWpGaD
Metolazone—CA7—Metabolism—CA9—kidney cancer	9.97e-05	0.000954	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CA9—kidney cancer	9.97e-05	0.000954	CbGpPWpGaD
Metolazone—Urticaria—Capecitabine—kidney cancer	9.96e-05	0.000525	CcSEcCtD
Metolazone—Abdominal pain—Capecitabine—kidney cancer	9.91e-05	0.000522	CcSEcCtD
Metolazone—Flatulence—Doxorubicin—kidney cancer	9.76e-05	0.000514	CcSEcCtD
Metolazone—Tension—Doxorubicin—kidney cancer	9.72e-05	0.000512	CcSEcCtD
Metolazone—CA4—Metabolism—CA2—kidney cancer	9.71e-05	0.00093	CbGpPWpGaD
Metolazone—Vomiting—Paclitaxel—kidney cancer	9.71e-05	0.000512	CcSEcCtD
Metolazone—Dysgeusia—Doxorubicin—kidney cancer	9.7e-05	0.000511	CcSEcCtD
Metolazone—Rash—Paclitaxel—kidney cancer	9.63e-05	0.000508	CcSEcCtD
Metolazone—Dermatitis—Paclitaxel—kidney cancer	9.62e-05	0.000507	CcSEcCtD
Metolazone—Nervousness—Doxorubicin—kidney cancer	9.62e-05	0.000507	CcSEcCtD
Metolazone—Back pain—Doxorubicin—kidney cancer	9.58e-05	0.000505	CcSEcCtD
Metolazone—Headache—Paclitaxel—kidney cancer	9.57e-05	0.000505	CcSEcCtD
Metolazone—CA9—Cellular responses to stress—HIF1A—kidney cancer	9.56e-05	0.000915	CbGpPWpGaD
Metolazone—Muscle spasms—Doxorubicin—kidney cancer	9.52e-05	0.000502	CcSEcCtD
Metolazone—CA4—Metabolism—ALAD—kidney cancer	9.47e-05	0.000906	CbGpPWpGaD
Metolazone—Vision blurred—Doxorubicin—kidney cancer	9.33e-05	0.000492	CcSEcCtD
Metolazone—CA4—Metabolism—ST3GAL2—kidney cancer	9.24e-05	0.000885	CbGpPWpGaD
Metolazone—Hypersensitivity—Capecitabine—kidney cancer	9.24e-05	0.000487	CcSEcCtD
Metolazone—CA9—Metabolism—GLIPR1—kidney cancer	9.23e-05	0.000884	CbGpPWpGaD
Metolazone—CA9—Metabolism—PPAT—kidney cancer	9.23e-05	0.000884	CbGpPWpGaD
Metolazone—CA12—Metabolism—CA9—kidney cancer	9.23e-05	0.000884	CbGpPWpGaD
Metolazone—Ill-defined disorder—Doxorubicin—kidney cancer	9.19e-05	0.000484	CcSEcCtD
Metolazone—Anaemia—Doxorubicin—kidney cancer	9.15e-05	0.000482	CcSEcCtD
Metolazone—Agitation—Doxorubicin—kidney cancer	9.1e-05	0.00048	CcSEcCtD
Metolazone—CA5A—Metabolism—CRABP1—kidney cancer	9.08e-05	0.000869	CbGpPWpGaD
Metolazone—Nausea—Paclitaxel—kidney cancer	9.07e-05	0.000478	CcSEcCtD
Metolazone—CA4—Metabolism—ALDH1A1—kidney cancer	9.03e-05	0.000865	CbGpPWpGaD
Metolazone—Asthenia—Capecitabine—kidney cancer	8.99e-05	0.000474	CcSEcCtD
Metolazone—Malaise—Doxorubicin—kidney cancer	8.93e-05	0.000471	CcSEcCtD
Metolazone—Vertigo—Doxorubicin—kidney cancer	8.9e-05	0.000469	CcSEcCtD
Metolazone—Syncope—Doxorubicin—kidney cancer	8.88e-05	0.000468	CcSEcCtD
Metolazone—Pruritus—Capecitabine—kidney cancer	8.87e-05	0.000468	CcSEcCtD
Metolazone—Leukopenia—Doxorubicin—kidney cancer	8.86e-05	0.000467	CcSEcCtD
Metolazone—Palpitations—Doxorubicin—kidney cancer	8.75e-05	0.000461	CcSEcCtD
Metolazone—Loss of consciousness—Doxorubicin—kidney cancer	8.7e-05	0.000459	CcSEcCtD
Metolazone—CA4—Metabolism—SLC5A3—kidney cancer	8.66e-05	0.000829	CbGpPWpGaD
Metolazone—CA4—Metabolism—PGK1—kidney cancer	8.66e-05	0.000829	CbGpPWpGaD
Metolazone—Cough—Doxorubicin—kidney cancer	8.64e-05	0.000455	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—ABCB1—kidney cancer	8.62e-05	0.000825	CbGpPWpGaD
Metolazone—CA9—Metabolism—APRT—kidney cancer	8.58e-05	0.000822	CbGpPWpGaD
Metolazone—CA9—Metabolism—FH—kidney cancer	8.58e-05	0.000822	CbGpPWpGaD
Metolazone—Diarrhoea—Capecitabine—kidney cancer	8.58e-05	0.000452	CcSEcCtD
Metolazone—Hypertension—Doxorubicin—kidney cancer	8.55e-05	0.000451	CcSEcCtD
Metolazone—CA4—Metabolism—LDHB—kidney cancer	8.49e-05	0.000813	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CRABP1—kidney cancer	8.47e-05	0.000811	CbGpPWpGaD
Metolazone—CA7—Metabolism—CRABP1—kidney cancer	8.47e-05	0.000811	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ITPR2—kidney cancer	8.44e-05	0.000808	CbGpPWpGaD
Metolazone—Chest pain—Doxorubicin—kidney cancer	8.43e-05	0.000444	CcSEcCtD
Metolazone—Arthralgia—Doxorubicin—kidney cancer	8.43e-05	0.000444	CcSEcCtD
Metolazone—Anxiety—Doxorubicin—kidney cancer	8.4e-05	0.000443	CcSEcCtD
Metolazone—Discomfort—Doxorubicin—kidney cancer	8.33e-05	0.000439	CcSEcCtD
Metolazone—Dizziness—Capecitabine—kidney cancer	8.29e-05	0.000437	CcSEcCtD
Metolazone—Dry mouth—Doxorubicin—kidney cancer	8.24e-05	0.000435	CcSEcCtD
Metolazone—CA9—Metabolism—GPC3—kidney cancer	8.07e-05	0.000773	CbGpPWpGaD
Metolazone—Vomiting—Capecitabine—kidney cancer	7.97e-05	0.00042	CcSEcCtD
Metolazone—Shock—Doxorubicin—kidney cancer	7.95e-05	0.000419	CcSEcCtD
Metolazone—Thrombocytopenia—Doxorubicin—kidney cancer	7.91e-05	0.000417	CcSEcCtD
Metolazone—Rash—Capecitabine—kidney cancer	7.9e-05	0.000417	CcSEcCtD
Metolazone—Dermatitis—Capecitabine—kidney cancer	7.9e-05	0.000416	CcSEcCtD
Metolazone—CA7—Metabolism—ITPR2—kidney cancer	7.88e-05	0.000754	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ITPR2—kidney cancer	7.88e-05	0.000754	CbGpPWpGaD
Metolazone—Headache—Capecitabine—kidney cancer	7.85e-05	0.000414	CcSEcCtD
Metolazone—CA12—Metabolism—CRABP1—kidney cancer	7.85e-05	0.000752	CbGpPWpGaD
Metolazone—CA9—Metabolism—CA2—kidney cancer	7.85e-05	0.000752	CbGpPWpGaD
Metolazone—Anorexia—Doxorubicin—kidney cancer	7.7e-05	0.000406	CcSEcCtD
Metolazone—CA5A—Metabolism—ACHE—kidney cancer	7.69e-05	0.000737	CbGpPWpGaD
Metolazone—CA5A—Metabolism—GSTT1—kidney cancer	7.69e-05	0.000737	CbGpPWpGaD
Metolazone—CA9—Metabolism—ALAD—kidney cancer	7.65e-05	0.000732	CbGpPWpGaD
Metolazone—CA9—Metabolism—ST3GAL2—kidney cancer	7.47e-05	0.000715	CbGpPWpGaD
Metolazone—Nausea—Capecitabine—kidney cancer	7.45e-05	0.000393	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Doxorubicin—kidney cancer	7.36e-05	0.000388	CcSEcCtD
Metolazone—CA4—Metabolism—CA9—kidney cancer	7.36e-05	0.000705	CbGpPWpGaD
Metolazone—Insomnia—Doxorubicin—kidney cancer	7.31e-05	0.000385	CcSEcCtD
Metolazone—CA12—Metabolism—ITPR2—kidney cancer	7.3e-05	0.000699	CbGpPWpGaD
Metolazone—CA9—Metabolism—ALDH1A1—kidney cancer	7.3e-05	0.000699	CbGpPWpGaD
Metolazone—CA5A—Metabolism—SCARB1—kidney cancer	7.28e-05	0.000697	CbGpPWpGaD
Metolazone—Paraesthesia—Doxorubicin—kidney cancer	7.26e-05	0.000383	CcSEcCtD
Metolazone—CA5A—Metabolism—PTGS1—kidney cancer	7.21e-05	0.00069	CbGpPWpGaD
Metolazone—Somnolence—Doxorubicin—kidney cancer	7.18e-05	0.000379	CcSEcCtD
Metolazone—CA7—Metabolism—GSTT1—kidney cancer	7.18e-05	0.000688	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GSTT1—kidney cancer	7.18e-05	0.000688	CbGpPWpGaD
Metolazone—CA7—Metabolism—ACHE—kidney cancer	7.18e-05	0.000688	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ACHE—kidney cancer	7.18e-05	0.000688	CbGpPWpGaD
Metolazone—Dyspepsia—Doxorubicin—kidney cancer	7.11e-05	0.000375	CcSEcCtD
Metolazone—CA5A—Metabolism—PSMD7—kidney cancer	7.07e-05	0.000677	CbGpPWpGaD
Metolazone—Decreased appetite—Doxorubicin—kidney cancer	7.02e-05	0.00037	CcSEcCtD
Metolazone—CA9—Metabolism—PGK1—kidney cancer	7e-05	0.00067	CbGpPWpGaD
Metolazone—CA9—Metabolism—SLC5A3—kidney cancer	7e-05	0.00067	CbGpPWpGaD
Metolazone—Fatigue—Doxorubicin—kidney cancer	6.97e-05	0.000367	CcSEcCtD
Metolazone—Pain—Doxorubicin—kidney cancer	6.91e-05	0.000364	CcSEcCtD
Metolazone—Constipation—Doxorubicin—kidney cancer	6.91e-05	0.000364	CcSEcCtD
Metolazone—CA9—Metabolism—LDHB—kidney cancer	6.86e-05	0.000657	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—CDKN2A—kidney cancer	6.84e-05	0.000654	CbGpPWpGaD
Metolazone—CA7—Metabolism—SCARB1—kidney cancer	6.8e-05	0.000651	CbGpPWpGaD
Metolazone—CA5B—Metabolism—SCARB1—kidney cancer	6.8e-05	0.000651	CbGpPWpGaD
Metolazone—CA7—Metabolism—PTGS1—kidney cancer	6.73e-05	0.000644	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PTGS1—kidney cancer	6.73e-05	0.000644	CbGpPWpGaD
Metolazone—CA5A—Metabolism—BCHE—kidney cancer	6.7e-05	0.000642	CbGpPWpGaD
Metolazone—Feeling abnormal—Doxorubicin—kidney cancer	6.66e-05	0.000351	CcSEcCtD
Metolazone—CA12—Metabolism—GSTT1—kidney cancer	6.66e-05	0.000637	CbGpPWpGaD
Metolazone—CA12—Metabolism—ACHE—kidney cancer	6.66e-05	0.000637	CbGpPWpGaD
Metolazone—CA5A—Metabolism—SLC5A5—kidney cancer	6.62e-05	0.000634	CbGpPWpGaD
Metolazone—Gastrointestinal pain—Doxorubicin—kidney cancer	6.61e-05	0.000348	CcSEcCtD
Metolazone—CA5B—Metabolism—PSMD7—kidney cancer	6.6e-05	0.000632	CbGpPWpGaD
Metolazone—CA7—Metabolism—PSMD7—kidney cancer	6.6e-05	0.000632	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—RELA—kidney cancer	6.58e-05	0.00063	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—MTOR—kidney cancer	6.45e-05	0.000618	CbGpPWpGaD
Metolazone—Urticaria—Doxorubicin—kidney cancer	6.42e-05	0.000338	CcSEcCtD
Metolazone—CA5A—Metabolism—SLC2A1—kidney cancer	6.39e-05	0.000612	CbGpPWpGaD
Metolazone—Abdominal pain—Doxorubicin—kidney cancer	6.39e-05	0.000337	CcSEcCtD
Metolazone—CA12—Metabolism—SCARB1—kidney cancer	6.3e-05	0.000603	CbGpPWpGaD
Metolazone—CA4—Metabolism—CRABP1—kidney cancer	6.26e-05	0.000599	CbGpPWpGaD
Metolazone—CA7—Metabolism—BCHE—kidney cancer	6.26e-05	0.000599	CbGpPWpGaD
Metolazone—CA5B—Metabolism—BCHE—kidney cancer	6.26e-05	0.000599	CbGpPWpGaD
Metolazone—CA12—Metabolism—PTGS1—kidney cancer	6.24e-05	0.000597	CbGpPWpGaD
Metolazone—CA7—Metabolism—SLC5A5—kidney cancer	6.18e-05	0.000592	CbGpPWpGaD
Metolazone—CA5B—Metabolism—SLC5A5—kidney cancer	6.18e-05	0.000592	CbGpPWpGaD
Metolazone—CA12—Metabolism—PSMD7—kidney cancer	6.12e-05	0.000585	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—CDKN1B—kidney cancer	6.05e-05	0.00058	CbGpPWpGaD
Metolazone—CA7—Metabolism—SLC2A1—kidney cancer	5.97e-05	0.000572	CbGpPWpGaD
Metolazone—CA5B—Metabolism—SLC2A1—kidney cancer	5.97e-05	0.000572	CbGpPWpGaD
Metolazone—Hypersensitivity—Doxorubicin—kidney cancer	5.95e-05	0.000314	CcSEcCtD
Metolazone—CA4—Metabolism—ITPR2—kidney cancer	5.82e-05	0.000557	CbGpPWpGaD
Metolazone—Asthenia—Doxorubicin—kidney cancer	5.8e-05	0.000306	CcSEcCtD
Metolazone—CA12—Metabolism—BCHE—kidney cancer	5.8e-05	0.000555	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—JUN—kidney cancer	5.76e-05	0.000552	CbGpPWpGaD
Metolazone—CA12—Metabolism—SLC5A5—kidney cancer	5.73e-05	0.000548	CbGpPWpGaD
Metolazone—Pruritus—Doxorubicin—kidney cancer	5.72e-05	0.000301	CcSEcCtD
Metolazone—CA12—Metabolism—SLC2A1—kidney cancer	5.53e-05	0.000529	CbGpPWpGaD
Metolazone—Diarrhoea—Doxorubicin—kidney cancer	5.53e-05	0.000291	CcSEcCtD
Metolazone—Dizziness—Doxorubicin—kidney cancer	5.34e-05	0.000282	CcSEcCtD
Metolazone—CA5A—Metabolism—GSTP1—kidney cancer	5.33e-05	0.000511	CbGpPWpGaD
Metolazone—CA4—Metabolism—GSTT1—kidney cancer	5.31e-05	0.000508	CbGpPWpGaD
Metolazone—CA4—Metabolism—ACHE—kidney cancer	5.31e-05	0.000508	CbGpPWpGaD
Metolazone—Vomiting—Doxorubicin—kidney cancer	5.14e-05	0.000271	CcSEcCtD
Metolazone—Rash—Doxorubicin—kidney cancer	5.1e-05	0.000269	CcSEcCtD
Metolazone—Dermatitis—Doxorubicin—kidney cancer	5.09e-05	0.000268	CcSEcCtD
Metolazone—Headache—Doxorubicin—kidney cancer	5.06e-05	0.000267	CcSEcCtD
Metolazone—CA9—Metabolism—CRABP1—kidney cancer	5.06e-05	0.000484	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ABCB1—kidney cancer	5.05e-05	0.000483	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—VEGFA—kidney cancer	5.03e-05	0.000482	CbGpPWpGaD
Metolazone—CA4—Metabolism—SCARB1—kidney cancer	5.02e-05	0.000481	CbGpPWpGaD
Metolazone—CA7—Metabolism—GSTP1—kidney cancer	4.98e-05	0.000477	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GSTP1—kidney cancer	4.98e-05	0.000477	CbGpPWpGaD
Metolazone—CA4—Metabolism—PTGS1—kidney cancer	4.97e-05	0.000476	CbGpPWpGaD
Metolazone—CA5A—Metabolism—GSTM1—kidney cancer	4.9e-05	0.000469	CbGpPWpGaD
Metolazone—CA4—Metabolism—PSMD7—kidney cancer	4.88e-05	0.000467	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—RAF1—kidney cancer	4.88e-05	0.000467	CbGpPWpGaD
Metolazone—Nausea—Doxorubicin—kidney cancer	4.8e-05	0.000253	CcSEcCtD
Metolazone—CA9—Cellular responses to stress—MAPK3—kidney cancer	4.76e-05	0.000456	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ABCB1—kidney cancer	4.71e-05	0.000451	CbGpPWpGaD
Metolazone—CA7—Metabolism—ABCB1—kidney cancer	4.71e-05	0.000451	CbGpPWpGaD
Metolazone—CA9—Metabolism—ITPR2—kidney cancer	4.7e-05	0.00045	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CYP1A1—kidney cancer	4.65e-05	0.000445	CbGpPWpGaD
Metolazone—CA4—Metabolism—BCHE—kidney cancer	4.62e-05	0.000443	CbGpPWpGaD
Metolazone—CA12—Metabolism—GSTP1—kidney cancer	4.61e-05	0.000442	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GSTM1—kidney cancer	4.58e-05	0.000438	CbGpPWpGaD
Metolazone—CA7—Metabolism—GSTM1—kidney cancer	4.58e-05	0.000438	CbGpPWpGaD
Metolazone—CA4—Metabolism—SLC5A5—kidney cancer	4.57e-05	0.000437	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—MAPK1—kidney cancer	4.53e-05	0.000434	CbGpPWpGaD
Metolazone—CA4—Metabolism—SLC2A1—kidney cancer	4.41e-05	0.000422	CbGpPWpGaD
Metolazone—CA12—Metabolism—ABCB1—kidney cancer	4.37e-05	0.000418	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CYP1A1—kidney cancer	4.34e-05	0.000415	CbGpPWpGaD
Metolazone—CA7—Metabolism—CYP1A1—kidney cancer	4.34e-05	0.000415	CbGpPWpGaD
Metolazone—CA9—Metabolism—GSTT1—kidney cancer	4.29e-05	0.000411	CbGpPWpGaD
Metolazone—CA9—Metabolism—ACHE—kidney cancer	4.29e-05	0.000411	CbGpPWpGaD
Metolazone—CA12—Metabolism—GSTM1—kidney cancer	4.24e-05	0.000406	CbGpPWpGaD
Metolazone—CA9—Metabolism—SCARB1—kidney cancer	4.06e-05	0.000389	CbGpPWpGaD
Metolazone—CA9—Metabolism—PTGS1—kidney cancer	4.02e-05	0.000385	CbGpPWpGaD
Metolazone—CA12—Metabolism—CYP1A1—kidney cancer	4.02e-05	0.000385	CbGpPWpGaD
Metolazone—CA9—Metabolism—PSMD7—kidney cancer	3.94e-05	0.000377	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—TP53—kidney cancer	3.8e-05	0.000364	CbGpPWpGaD
Metolazone—CA9—Metabolism—BCHE—kidney cancer	3.74e-05	0.000358	CbGpPWpGaD
Metolazone—CA9—Metabolism—SLC5A5—kidney cancer	3.69e-05	0.000353	CbGpPWpGaD
Metolazone—CA4—Metabolism—GSTP1—kidney cancer	3.68e-05	0.000352	CbGpPWpGaD
Metolazone—CA9—Metabolism—SLC2A1—kidney cancer	3.56e-05	0.000341	CbGpPWpGaD
Metolazone—CA4—Metabolism—ABCB1—kidney cancer	3.48e-05	0.000333	CbGpPWpGaD
Metolazone—CA5A—Metabolism—POMC—kidney cancer	3.46e-05	0.000332	CbGpPWpGaD
Metolazone—CA4—Metabolism—GSTM1—kidney cancer	3.38e-05	0.000324	CbGpPWpGaD
Metolazone—CA7—Metabolism—POMC—kidney cancer	3.23e-05	0.00031	CbGpPWpGaD
Metolazone—CA5B—Metabolism—POMC—kidney cancer	3.23e-05	0.00031	CbGpPWpGaD
Metolazone—CA4—Metabolism—CYP1A1—kidney cancer	3.2e-05	0.000307	CbGpPWpGaD
Metolazone—CA12—Metabolism—POMC—kidney cancer	3e-05	0.000287	CbGpPWpGaD
Metolazone—CA9—Metabolism—GSTP1—kidney cancer	2.97e-05	0.000285	CbGpPWpGaD
Metolazone—CA9—Metabolism—ABCB1—kidney cancer	2.81e-05	0.000269	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PTGS2—kidney cancer	2.76e-05	0.000265	CbGpPWpGaD
Metolazone—CA9—Metabolism—GSTM1—kidney cancer	2.73e-05	0.000262	CbGpPWpGaD
Metolazone—CA9—Metabolism—CYP1A1—kidney cancer	2.59e-05	0.000248	CbGpPWpGaD
Metolazone—CA7—Metabolism—PTGS2—kidney cancer	2.58e-05	0.000247	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PTGS2—kidney cancer	2.58e-05	0.000247	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PTEN—kidney cancer	2.41e-05	0.000231	CbGpPWpGaD
Metolazone—CA12—Metabolism—PTGS2—kidney cancer	2.39e-05	0.000229	CbGpPWpGaD
Metolazone—CA4—Metabolism—POMC—kidney cancer	2.39e-05	0.000229	CbGpPWpGaD
Metolazone—CA7—Metabolism—PTEN—kidney cancer	2.25e-05	0.000215	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PTEN—kidney cancer	2.25e-05	0.000215	CbGpPWpGaD
Metolazone—CA12—Metabolism—PTEN—kidney cancer	2.08e-05	0.0002	CbGpPWpGaD
Metolazone—CA9—Metabolism—POMC—kidney cancer	1.93e-05	0.000185	CbGpPWpGaD
Metolazone—CA4—Metabolism—PTGS2—kidney cancer	1.91e-05	0.000182	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PIK3CA—kidney cancer	1.7e-05	0.000163	CbGpPWpGaD
Metolazone—CA4—Metabolism—PTEN—kidney cancer	1.66e-05	0.000159	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PIK3CA—kidney cancer	1.59e-05	0.000152	CbGpPWpGaD
Metolazone—CA7—Metabolism—PIK3CA—kidney cancer	1.59e-05	0.000152	CbGpPWpGaD
Metolazone—CA9—Metabolism—PTGS2—kidney cancer	1.54e-05	0.000147	CbGpPWpGaD
Metolazone—CA12—Metabolism—PIK3CA—kidney cancer	1.47e-05	0.000141	CbGpPWpGaD
Metolazone—CA9—Metabolism—PTEN—kidney cancer	1.34e-05	0.000129	CbGpPWpGaD
Metolazone—CA4—Metabolism—PIK3CA—kidney cancer	1.17e-05	0.000112	CbGpPWpGaD
Metolazone—CA9—Metabolism—PIK3CA—kidney cancer	9.47e-06	9.07e-05	CbGpPWpGaD
